Company profile for Lonza Group

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Lonza is one of the world's leading and most-trusted suppliers to the Pharma&Biotech and Specialty Ingredient markets. We harness science and technology to create products that make people's and animals' lives healthier and that enhance the overall quality of life and well-being. Our products and services range from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from industrial preserva...
Lonza is one of the world's leading and most-trusted suppliers to the Pharma&Biotech and Specialty Ingredient markets. We harness science and technology to create products that make people's and animals' lives healthier and that enhance the overall quality of life and well-being. Our products and services range from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens, from the manufacture of vitamin B compounds and organic personal care ingredients to agricultural services and products.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Switzerland
Address
Address
Muenchensteinerstrasse 38 CH-4002 Basel
Telephone
Telephone
+41 61 316 81 11
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

CPhI North America

Not Confirmed

envelop Contact Supplier

CPhI North America

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

INTERVIEW #SpeakPharma

[Sponsored by another company]
Alchem NicSelect™ grants customers royalty-free access to T-MAX™ tech for 3-in-1 vape satisfaction in flavour-restricted markets
With increasing flavour bans in key markets, vaping brands are facing significant challenges in providing satisfying alternatives to vapers and smokers looking to transition. Recognising this need, Alchem NicSelect™ is making a bold move by offering its key customers royalty-free and unrestricted geographical access to its revolutionary T-MAX™ technology.“At Alchem NicSelect™, we understand the urgency for vaping brands to adapt to new regulations without compromising on satisfaction. By offering royalty-free access to T-MAX™ technology, we empower our customers to provide the closest cigarette-like experience possible, even in markets with strict flavour restrictions,” said Riccardo Santambrogio, Europe Sales Manager.HIGHLIGHTS// offering royalty-free access to T-MAX™ technology/ unrestricted geographical access/ closest cigarette-like experience Addressing the biggest barrier: Nicotine satisfactionOne of the primary reasons many vapers are dissatisfied and smokers struggle to switch to vaping is that traditional nicotine solutions fail to replicate the rapid satisfaction provided by cigarettes. Nicotine replacement therapies (NRTs) and even conventional vaping products often lack the immediate nicotine hit, throat feel, and overall experience that smokers are accustomed to. T-MAX™ solves this problem by engineering a nicotine experience that closely mimics cigarette consumption without relying on flavours.T-MAX™ provides a unique 3-in-1 approach:1. The Speed of a Cigarette – Rapid nicotine delivery and rush within seconds for immediate satisfaction.2. The Power of Nicotine Salts – A stronger perceived nicotine effect without exceeding legal limits (20 mg/ml nicotine limit under the European Tobacco Products Directive). With T-MAX™, 8 mg/ml feels like 20 mg/ml, and 14 mg/ml feels like 40 mg/ml.3. The Throat Hit of Freebase Nicotine – Especially in a flavour-free formulation, the combined ingredients in T-MAX™ deliver an even more satisfying throat feel than expected from nicotine base, much closer to and more familiar with a cigarette throat feel that habitual smokers recognise.HIGHLIGHTS// unique 3-in-1 approach/ rush within seconds/ stronger perceived nicotine effect without exceeding legal limits/ more satisfying throat feel that habitual smokers recogniseNo flavour, but not less satisfyingWhile flavours have traditionally played a role in vaping adoption, market realities are shifting. With flavour bans spreading across regions, brands need solutions that deliver satisfaction without relying on taste. Consumer research has shown that T-MAX™ performs exceptionally well even without added flavours. Since most cigarette smokers do not smoke for the tobacco flavour but rather for the nicotine hit and habitual experience, T-MAX™ provides a viable alternative that aligns with new regulatory landscapes.HIGHLIGHTS// flavour bans spreading across regions/ T-MAX™ performs exceptionally well even without added flavoursEmpowering vape brands with free access to T-MAX™By granting customers royalty-free access to the T-MAX™ technology, Alchem NicSelect™ is removing barriers for vaping brands and original equipment manufacturers (OEMs) looking to adapt to regulatory changes. This open-access approach ensures that manufacturers can integrate T-MAX™ into their product lines without additional costs, allowing them to offer superior nicotine satisfaction in markets where flavours are no longer an option.HIGHLIGHTS// removing barriers for vaping brands and OEMs looking to adapt/ manufacturers can integrate T-MAX™ into product lines without additional costsThe future of vaping in restricted marketsWith T-MAX™, the vaping industry has a powerful tool to retain customers and convert smokers who have struggled with traditional vaping products. By delivering the key elements of cigarette satisfaction — without combustion or flavours — T-MAX™ is set to redefine what a satisfying vape experience means in a post-flavour-ban world.“Our commitment to innovation and accessibility means we are providing our customers with the solutions they need to navigate an evolving regulatory landscape. T-MAX™ allows brands to offer a highly satisfying experience that mimics smoking without relying on flavours. The message is clear: no flavour, but not less satisfying”, added Santambrogio.HIGHLIGHTS// powerful tool to retain customers and convert smokers/ delivering the key elements of cigarette satisfaction without combustion or flavours/ no flavour, but not less satisfying

Impressions: 284

https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets

Radio Compass
06 May 2025

VLOG #PharmaReel

[Sponsored by another company]
This PharmaReel highlights Transo-Pharm USA’s offerings of premium Phyto Cannabidiol (CBD) and Phyto Cannabigerol (CBG) isolates from its cGMP-certified facility inspected by the FDA and ANVISA. The company has an expanded reach across the US and EU.

Impressions: 402

read-more

DATA COMPILATION #PharmaFlow

[Sponsored by another company]
DMF filings surge 44% in Q1 2025; India tops list with 51% rise in year-on-year submissions
The first quarter (Q1) of 2025 witnessed an impressive surge in Drug Master File (DMF) submissions to the US Food and Drug Administration (FDA), signaling a robust expansion in pharmaceutical development activities, the looming threat of tariffs notwithstanding.A total of 339 Type II DMFs were submitted during this period, as opposed to 235 submissions in Q1 2024, marking an exceptional increase of 44.26 percent. PharmaCompass’ data suggests that this is a record high for any first quarter.Overall, 440 DMFs were submitted across all categories (Types II, III, IV, and V) during Q1 2025, compared to 353 in the same period last year — representing a 24.65 percent increase.India and China continued to dominate the DMF landscape. India led with 162 submissions in Q1 2025, posting a remarkable 51.4 percent increase over 107 submissions recorded in Q1 2024. China followed with 135 submissions, representing a 33.66 percent increase over the 101 filings in Q1 2024.Taiwan sprung a surprise as a distant third. It made 12 DMF submissions in Q1 2025, as opposed to just one in Q1 2024. Western countries like the US, Spain, Germany, and Italy have maintained relatively stable or declining submission rates. Only the Netherlands showed significant growth with four DMF submissions in Q1 2025, up from zero in Q1 2024. View FDA DMF Filings in Q1 2025 (Power BI Dashboard, Free Excel Available)Indian giants MSN, Aurobindo, Cipla, Dr Reddy’s lead record-breaking DMF surgeIndia lived up to its “pharmacy of the world” reputation with the highest DMF submissions. In fact, seven of the top eight companies in the DMF tally were headquartered in India. MSN Group, emerged as the unequivocal leader with 23 submissions in Q1 2025, as against 15 in Q1 2024. Aurobindo Pharma increased its DMF activity from seven submissions in Q1 2024 to 12 in Q1 2025. Alivus Life Sciences, formerly known as Glenmark, made a dramatic leap with eight submissions in Q1 2025, quadrupling its previous year’s count of just two. Cipla more than doubled its DMF submissions — from three in Q1 2024 to eight in Q1 2025.Dr. Reddy’s Laboratories, one of India’s largest generic drugmakers, filed seven DMF submissions. The company’s Q1 2025 DMF portfolio includes high-value molecules like deucravacitinib, finerenone, enzalutamide, niraparib tosylate monohydrate, tucatinib, and tizanidine hydrochloride.Dr. Reddy’s has also indicated that they are open to manufacturing in the US. Meanwhile, Hetero Drugs filed seven submissions while Lee Pharma recorded six in Q1 2025.Chinese manufacturer Jiangsu East-Mab Biomedical Technology also established a significant presence with six DMFs. View FDA DMF Filings in Q1 2025 (Power BI Dashboard, Free Excel Available) Semaglutide, finerenone see most DMF submissions; first-time filings surge 64%Semaglutide and finerenone emerged as the most documented molecules in Q1 2025, each garnering nine DMF submissions. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that has revolutionized diabetes management and weight loss treatment, continues to attract significant manufacturer interest. Similarly, finerenone, a non-steroidal drug used in treating chronic kidney disease in type 2 diabetes patients, has garnered attention from manufacturers.Carfilzomib, used in multiple myeloma treatment, secured the third position with five DMF submissions. Deucravacitinib, a novel drug approved for moderate to severe plaque psoriasis, followed with four DMF submissions.There were several molecules with three DMF submissions each. Among them were tapinarof, a novel drug for psoriasis, and tirzepatide, a GLP-1/GIP receptor agonist that has shown remarkable efficacy in diabetes and weight management. During the quarter, 23 molecules received their inaugural DMF submissions. This number has risen by 64 percent since Q1 2024, when only 14 drugs saw their first DMF filings.In Q1 2025, these 23 first-time molecules collectively garnered 30 DMF submissions, with deucravacitinib emerging as the clear leader. Indian companies Dr. Reddy’s Laboratories and Cipla filed DMFs for this plaque psoriasis treatment as did Spain’s Curia and PMC Global.The Q1 2025 roster of first-time DMF filings include retatrutide (another GLP-1 receptor agonist), sotagliflozin, setmelanotide acetate, daridorexant, nusinersen, zavegepant, belzutifan, elacestrant dihydrochloride, selumetinib sulfate, sotorasib, atogepant, omadacycline tosylate, osilodrostat phosphate, ensifentrine, landiolol hydrochloride, maralixibat chloride, maribavir, methyl olivetolate, diazoxide choline, sparsentan, thinnertide, and vismodegib. View FDA DMF Filings in Q1 2025 (Power BI Dashboard, Free Excel Available) Our viewGiven Trump’s rhetoric around tariffs on imported drugs, the record-breaking DMF submissions in Q1 2025 sent out a strong message that the global pharmaceutical industry is willing to take on the complex geopolitical situation with resilience and strategic foresight.On a different note, the rise in DMF filings also indicate increased workload for the FDA staff, as also more inspections by the agency. It seems like more ‘laid off’ FDA employees will be asked to return to work in the coming days.

Impressions: 570

https://www.pharmacompass.com/radio-compass-blog/dmf-filings-surge-44-in-q1-2025-india-tops-list-with-51-rise-in-year-on-year-submissions

#PharmaFlow by PHARMACOMPASS
15 May 2025

NEWS #PharmaBuzz

read-more
read-more

https://www.contractpharma.com/breaking-news/lonza-appoints-andreas-bohrer-as-chief-legal-corporate-affairs-officer/

CONTRACTPHARMA
15 May 2025

https://www.indianpharmapost.com/news/lonza-joins-cmac-to-enhance-service-offering-for-specialty-enhanced-drug-product-and-particle-technologies-17024

INDPHARMAPOST
15 Apr 2025

https://www.contractpharma.com/breaking-news/ethris-and-lonza-collaborate-to-develop-spray-dried-mrna-vaccines/

CONTRACTPHARMA
07 Apr 2025

https://www.indianpharmapost.com/news/lonza-implements-streamlined-operating-model-16961

INDPHARMAPOST
01 Apr 2025

https://www.exogenus-t.com/2025/03/11/exogenus-therapeutics-chooses-lonza-to-develop-a-gmp-compliant-process-to-manufacture-exo-101-its-lead-exosome-based-candidate/

PRESS RELEASE
11 Mar 2025

https://www.pharmiweb.com/press-release/2025-01-29/lonza-delivers-solid-2024-performance-with-cer-sales-in-line-with-prior-year-and-290-core-ebitda-m

PHARMAWEB
28 Jan 2025

Services

Upload your portfolio for free, ask us

API & Drug Product Development

Click here to discover the service providers for API & Drug Product Development

Excipients

Click here to find the perfect excipient manufacturers by their capabilities

Inspections and registrations

Upload your audits for free, ask us

ABOUT THIS PAGE

Contact Lonza Group and get a quotation

Lonza Group is a supplier offers 79 products (APIs, Excipients or Intermediates).

Find a price of Nicotinamide bulk with CEP, JDMF offered by Lonza Group

Find a price of Desmopressin Acetate bulk with CEP offered by Lonza Group

Find a price of Niacin bulk with CEP offered by Lonza Group

Find a price of Bovine Serum bulk with CEP offered by Lonza Group

Find a price of Fluvoxamine bulk with DMF offered by Lonza Group

Find a price of Nicotinamide bulk with DMF offered by Lonza Group

Find a price of Sirolimus bulk with DMF offered by Lonza Group

Find a price of Voclosporin bulk with DMF offered by Lonza Group

Find a price of MC-VAL-ALA-PBD bulk with DMF offered by Lonza Group

Find a price of EC-125 DRUG SUBSTANCE bulk with DMF offered by Lonza Group

Find a price of Medium / medium additive · CHO trace element solution bulk with JDMF offered by Lonza Group

Find a price of Medium / medium additive · CHO feed-based F bulk with JDMF offered by Lonza Group

Find a price of Medium / medium additive · CHO feed base A bulk with JDMF offered by Lonza Group

Find a price of Medium / Medium Additives-CHO7 Liposome Solution bulk with JDMF offered by Lonza Group

Find a price of Medium / Medium Additives-ProCHO5 bulk with JDMF offered by Lonza Group

Find a price of Medium / Medium Additives-Power Feed A Power Kit (Power Feed A (without lipids)) bulk with JDMF offered by Lonza Group

Find a price of Medium / Medium Additives ・ X-VIVO 15 Medium with transferrin without phenol red or gentamicin bulk with JDMF offered by Lonza Group

Find a price of Cell · Lonza Walkersville bone marrow stem cells bulk with JDMF offered by Lonza Group

Find a price of Medium / medium additive · CHO vitamin mixture bulk with JDMF offered by Lonza Group

Find a price of Medium / medium additive · CHO feed-based E bulk with JDMF offered by Lonza Group

Find a price of Medium / media supplements · Lonza Walkersville PowerCHO2-C D bulk with JDMF offered by Lonza Group

Find a price of Medium / Medium Additives-Lonza Walkersville X-VIVO 15 bulk with JDMF offered by Lonza Group

Find a price of Medium / Medium Additives-Power CHO-2 Powerer Kit (Power CHO-2 Medium) bulk with JDMF offered by Lonza Group

Find a price of Medium / Medium Additives ProPER-1 basal powerer w / 6g / L Gluc & 6 mM L-Gln bulk with JDMF offered by Lonza Group

Find a price of Medium / Medium Additives-PowerCHO-2 CD_Verviers bulk with JDMF offered by Lonza Group

Find a price of Medium / medium additive · Lonza Walkersville ProCHO-5 bulk with JDMF offered by Lonza Group

Find a price of Medium / medium additive supplement E bulk with JDMF offered by Lonza Group

Find a price of Medium / medium additive · CHO feed base D bulk with JDMF offered by Lonza Group

Find a price of Medium / Medium Additives-PowerCHO-2 bulk with JDMF offered by Lonza Group

Find a price of Medium / medium additive · Lonza Verviers X-VIVO 15 bulk with JDMF offered by Lonza Group

Find a price of Medium / Medium Additives-CHO7 Lipids bulk with JDMF offered by Lonza Group

Find a price of Medium / Medium Additive / CHO Feed Base B bulk with JDMF offered by Lonza Group

Find a price of Medium / Medium Additives-PowerCHO-2_Verviers bulk with JDMF offered by Lonza Group

Find a price of 1-Mercaptomethyl-Cyclopropyl-Acetic Acid bulk offered by Lonza Group

Find a price of 7-Hydroxystaurosporine bulk offered by Lonza Group

Find a price of Alimemazine bulk offered by Lonza Group

Find a price of Auranofin bulk offered by Lonza Group

Find a price of Bovine Serum bulk offered by Lonza Group

Find a price of Bromfenac Sodium bulk offered by Lonza Group

Find a price of Desmopressin Acetate bulk offered by Lonza Group

Find a price of Eflornithine Hydrochloride bulk offered by Lonza Group

Find a price of Eprosartan bulk offered by Lonza Group

Find a price of Eprosartan Mesylate bulk offered by Lonza Group

Find a price of Etodolac bulk offered by Lonza Group

Find a price of Ketosulfone bulk offered by Lonza Group

Find a price of L-Carnitine Tartrate bulk offered by Lonza Group

Find a price of Levocarnitine bulk offered by Lonza Group

Find a price of Luteolin bulk offered by Lonza Group

Find a price of Motexafin Gadolinium bulk offered by Lonza Group

Find a price of Niacin bulk offered by Lonza Group

Find a price of P-Hydroxyamphetamine bulk offered by Lonza Group

Find a price of Phenoxybenzamine HCl bulk offered by Lonza Group

Find a price of Prochlorperazine Edisylate bulk offered by Lonza Group

Find a price of Propylhexedrine bulk offered by Lonza Group

Find a price of Thymidine bulk offered by Lonza Group

Find a price of Tranylcypromine Sulfate bulk offered by Lonza Group

Find a price of Triamterene bulk offered by Lonza Group

Find a price of Voclosporin bulk offered by Lonza Group

Find a price of DEBMEB bulk offered by Lonza Group

Find a price of CRUDE SG-3249 bulk offered by Lonza Group

Find a price of SECAMINE HYDROCHLORIDE bulk offered by Lonza Group

Find a price of SB 200473 bulk offered by Lonza Group

Find a price of SB 201999 bulk offered by Lonza Group

Find a price of FACILITY AND OPERATING PROCEDURES IN VISP, SWITZERLAND bulk offered by Lonza Group

Find a price of EC-037 bulk offered by Lonza Group

Find a price of D5AA bulk offered by Lonza Group

Find a price of TP4 bulk offered by Lonza Group

Find a price of SB 217063 AND SK&F 109077 bulk offered by Lonza Group

Find a price of BULK PURIFIED HUMAN MONOCLONAL ANTIBODY (ANTI-IL8) (NSO CELLS, LONZA) TO IL-8 bulk offered by Lonza Group

Find a price of CN 343 (SAS) bulk offered by Lonza Group

Find a price of 2-BUTYL-3-H-IMIDAZOL-4-CARBALDEHYDE (IMALOC SB 202783) bulk offered by Lonza Group

Find a price of TERT-BUTYL (S)-3-(TERT-BUTYLCARBAMOYL) PIPERAZINE-1-CARBOXYLATE bulk offered by Lonza Group

Find a price of Benzethonium Chloride bulk offered by Lonza Group

Find a price of Eslicarbazepine Acetate bulk offered by Lonza Group

Find a price of Lenalidomide bulk offered by Lonza Group

Find a price of Macitentan bulk offered by Lonza Group

Find a price of Sodium bulk offered by Lonza Group

Find a price of Zilpaterol HCl bulk offered by Lonza Group

Find a price of PMT (20,23-DIPIPERIDINLY-MYCAMINOSYL-TYLONOLIDE) bulk offered by Lonza Group

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty